Summary by Futu AI
On October 1, 2024, Mangoceuticals, Inc., also known as MangoRx, announced the launch of its new oral Semaglutide weight loss treatment named 'Slim.' The product is now available for purchase on the company's telemedicine platform. This launch represents a significant step for MangoRx in addressing the growing global GLP-1 market, which is projected to expand from $49.3 billion in 2024 to $157.5 billion by 2035. 'Slim' is offered as an oral dissolvable tablet compounded with Vitamin B6, providing a convenient alternative to injections. MangoRx's CEO, Jacob Cohen, expressed optimism about the product's potential to meet increasing consumer demand for effective weight management solutions. The company has competitively priced 'Slim' at $299 per month, aiming to make the treatment accessible to a broad customer base. MangoRx focuses on men's health and wellness products and services, including erectile dysfunction, hair growth, hormone replacement therapies, and weight management, all available through its secure telemedicine platform.